Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Refractory CTCL and ATL
NCT00699296Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2008
- Primary completion
- Dec 2008
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in cutaneous T-cell lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATLL), sponsored by Novartis. Started May 2008; status: terminated.
02
Drugs
panobinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00699296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00699296.